FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 307 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New Cancer Model Shows Promise in Predicting If Treatment Will Shrink... July 28, 2022 EMA Recommends Extending Indications for Decitabine / Cedazuridine May 29, 2026 What to Know About the Different Types of Mastectomies for Breast... March 2, 2023 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 Load more HOT NEWS FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer How I Navigated Being a Young Mom During Cancer: A Survivor’s... Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer Mouse Study Points to Strategy for Preserving Bone During Chemotherapy
